Here are the Form 4 insider transactions from RenX Enterprises Corp. (RENX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RENX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RENX filings page.
RenX Enterprises Corp. (RENX) director Jeffrey C. Tweedy received a grant of 8,318 stock options on October 13, 2026, for 8,318 shares of common stock. The options have an exercise price of $1.54 per share and expire October 12, 2036. They vest pro rata monthly over six months starting November 13, 2026, subject to his continued service through each vesting date. His reported option holdings after the grant were 8,318.
RenX Enterprises Corp. director Christopher Melton received a grant of 8,254 stock options on October 13, 2026, to acquire 8,254 shares of Common Stock. The options have an exercise price of $1.54 per share and expire October 12, 2036. They vest pro rata monthly over six months beginning November 13, 2026, subject to his continued service through each vesting date.
RenX Enterprises Corp. (RENX) director J. Scott Magrane received a grant of 8,294 stock options on October 13, 2026. The options cover 8,294 common shares, have a $1.54 exercise price, and expire October 12, 2036. They vest pro rata monthly over six months beginning November 13, 2026, subject to continued service through each vesting date.
RenX Enterprises Corp. director Bjarne Erik Siwert Borg acquired 8,500 stock options on October 13, 2026. The options are for common stock, carry an exercise price of $1.54 per share, and vest pro rata monthly over six months beginning November 13, 2026, subject to his continued service through each vesting date.
RenX Enterprises Corp. director Peter G. DeMaria received an award of 8,294 stock options covering 8,294 common shares on October 13, 2026. The options have a $1.54-per-share exercise price and vest pro rata monthly over six months beginning November 13, 2026, subject to his continued service through each vesting date.
RenX Enterprises Corp. (symbol: RENX) is the issuer of record for a Form 4 filing submitted to the SEC. Brune Nicolai Ayrton reported acquisition or exercise transactions in this Form 4 filing.
RenX Enterprises Corp. (RENX) reported that its Chief Financial Officer, Brune Nicolai Ayrton, received a grant of 50,000 restricted stock units (RSUs) of common stock on September 8, 2026. The award was reported at $0.00 per share and is held as direct ownership.
After this grant, the CFO directly holds 51,382 shares/RSUs-equivalent of RenX common stock. The 50,000 RSUs vest in two equal installments, one-half on September 30, 2026 and the balance on March 31, 2027. No Rule 10b5-1 trading plan is indicated for this award.
RenX Enterprises Corp. (symbol: RENX) is the issuer of record for a Form 4 filing submitted to the SEC. Villarreal David Roberto reported acquisition or exercise transactions in this Form 4 filing.
RenX Enterprises Corp. (RENX) reported that Chief Executive Officer and director David Roberto Villarreal received an equity award of 72,500 restricted stock units (RSUs) of common stock on September 8, 2026. Each RSU represents a contingent right to receive one share of common stock, with no cash purchase price.
The RSUs vest in two tranches, with one-half vesting on September 30, 2026 and the remainder vesting on March 31, 2027. Following this grant, Villarreal directly holds 75,723 shares of RenX Enterprises Corp. common stock, including the awarded RSUs. No Rule 10b5-1 trading plan is reported for this award.
RenX Enterprises Corp. director Bjarne Erik Siwert Borg reported that Index Equity US LLC, an entity he manages, acquired derivatives tied to the company. On June 11, 2026, Index Equity received 7,169 shares of Series C Convertible Preferred Stock and a warrant to buy up to 619,084 shares of common stock. These were issued in exchange for $7,169,072.79 of principal and accrued interest on a promissory note. The preferred shares are initially convertible into 2,476,338.51 common shares at $2.895 per share, with a floor of $1.50, and both the preferred conversion and warrant exercise require prior stockholder approval under Nasdaq rules.